Cancer Biomarkers Market by Profiling Technology (Omic Technologies, Imaging Technologies, Immunoassays, and Cytogenetics Based Tests), Biomolecule (Genetic Biomarkers, Protein Biomarkers, and Glyco-biomarkers), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Stomach Cancer, and Others), and Application (Diagnostics, Drug Discovery and Development, Prognostics,Risk Assessment, and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027

1.1.Report description40

1.2.Key benefits for stakeholders41

1.3.Key market segments43

1.3.1.List of key players profiled in the report45

1.4.Research methodology46

1.4.1.Secondary research48

1.4.2.Primary research48

1.4.3.Analyst tools and models49

CHAPTER 2:EXECUTIVE SUMMARY50

2.1.Key findings of the study52

2.2.CXO perspective53

CHAPTER 3:MARKET OVERVIEW54

3.1.Market definition and scope54

3.2.Biomarker Diagnosis vs. Conventional Diagnosis56

3.3.Key findings57

3.3.1.Top investment pockets57

3.4.Porter's five forces analysis59

3.4.1.Bargaining power of buyers59

3.4.2.Bargaining power of suppliers60

3.4.3.Thereat of new entrants61

3.4.4.Threat of substitutes62

3.4.5.Intensity of competitive rivalry63

3.5.Top player positioning, 201964

3.6.Market dynamics65

3.6.1.Drivers65

3.6.1.1.Rise in incidence and prevalence of various cancer types65

3.6.1.2.Growth in importance of biological and targeted drug therapies67

3.6.1.3.Increase in acquisitions and collaborations69

3.6.1.4.Increase in technological advancements70

3.6.1.5.High accuracy and reliability70

3.6.1.6.Rise in investment from government, public, and private sectors70

3.6.1.7.Increase in clinical trials71

3.6.1.8.Growth in popularity of personalized medicine and companion diagnostics71

3.6.2.Restraint72

3.6.2.1.High cost of drug development and threat of failure72

3.6.2.2.Unregulated government regulation and reimbursement policies72

3.6.2.3.Adverse effects of cancer drug therapy73

3.6.3.Opportunity73

3.6.3.1.Advancement of cancer drugs research73

3.6.3.2.Increased focus towards advanced treatment protocols74

3.6.3.3.Significant unmet need in cancer diagnosis74

3.6.3.4.Increased awareness to reduce healthcare costs74

3.6.3.5.Opportunities in emerging economies75

3.6.4.Impact Analyses75

3.7.PATENT ANALYSIS76

3.8.Clinical Trials Analysis78

CHAPTER 4:CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY79

4.1.Overview79

4.1.1.Market size and forecast, by profiling technologies80

4.2.OMIC TECHNOLOGIES82

4.2.1.Key market trends and growth opportunities82

4.2.2.Market size and forecast, by region83

4.2.3.Market analysis, by country84

4.2.4.Market size and forecast, by type85

4.2.5.Genomics86

4.2.5.1.Market Size and forecast87

4.2.5.2.Next Generation Sequencing (NGS)88

4.2.5.3.Microarray89

4.2.5.4.Polymerase chain reaction (PCR)89

4.2.6.Proteomics90

4.2.6.1.Market size and forecast90

4.2.6.2.Mass spectrometry92

4.2.6.3.2D gel electrophoresis92

4.2.6.4.Protein microarray technology93

4.2.6.5.Antibody array technology94

4.2.6.6.Peptide array technology94

4.2.7.Other omic technologies95

4.2.7.1.Market size and forecast95

4.2.7.2.Metabolomics96

4.2.7.3.Glycomics97

4.3.IMAGING TECHNOLOGIES97

4.3.1.Key market trends and growth opportunities97

4.3.2.Market size and forecast, by region98

4.3.3.Market analysis, by countries99

4.3.4.Market size and forecast, by type100

4.3.5.Magnetic resonance imaging (MRI)101

4.3.5.1.Market size and forecast102

4.3.6.Positron emission tomography (PET)103

4.3.6.1.Market size and forecast103

4.3.7.Computed tomography (CT)104

4.3.7.1.Market size and forecast105

4.3.8.Mammography105

4.3.8.1.Market size and forecast106

4.3.9.Ultrasound107

4.3.9.1.Market size and forecast107

4.4.IMMUNOASSAYS108

4.4.1.Key market trends and growth opportunities109

4.4.2.Market size and forecast, by region109

4.4.3.Market analysis, by country110

4.4.4.Market size and forecast, by type112

4.4.5.Immunohistochemistry (IHC) tests113

4.4.5.1.Market size and forecast113

4.4.6.Enzyme-linked immunosorbent assay (ELISA)114

4.4.6.1.Market size and forecast114

4.4.7.Flow cytometry115

4.4.7.1.Market size and forecast116

4.5.CYTOGENETICS-BASED TESTS117

4.5.1.Key market trends and growth opportunities117

4.5.2.Market size and forecast, by region118

4.5.3.Market analysis, by country119

4.5.4.Market size and forecast, by type120

4.5.5.In-situ hybridization121

4.5.5.1.Market size and forecast121

4.5.6.Others122

4.5.6.1.Market size and forecast122

CHAPTER 5:CANCER BIOMARKERS MARKET, BY BIOMOLECULE124

5.1.Overview124

5.1.1.Market size and forecast125

5.2.Genetic Biomarkers126

5.2.1.Market size and forecast, by region128

5.2.2.Market analysis, by country129

5.3.Protein Biomarkers130

5.3.1.Market size and forecast, by region130

5.3.2.Market analysis, by country131

5.4.Glyco-Biomarkers133

5.4.1.Market size and forecast, by region134

5.4.2.Market analysis, by country135CHAPTER 6:CANCER BIOSENSORS MARKET, BY CANCER TYPE136

6.1.Overview136

6.1.1.Market size and forecast137

6.2.Breast Cancer138

6.2.1.Market size and forecast, by region139

6.2.2.Market analysis, by country140

6.3.Lung Cancer141

6.3.1.Market size and forecast, by region141

6.3.2.Market analysis, by country142

6.4.Colorectal cancer143

6.4.1.Market size and forecast, by region144

6.4.2.Market analysis, by country145

6.5.Prostate cancer146

6.5.1.Market size and forecast, by region147

6.5.2.Market analysis, by country148

6.6.Stomach cancer149

6.6.1.Market size and forecast, by region150

6.6.2.Market analysis, by country150

6.7.Others152

6.7.1.Market size and forecast, by region152

6.7.2.Market analysis, by country153

CHAPTER 7:CANCER BIOMARKER MARKET, BY APPLICATION155

7.1.Overview155

7.1.1.Market size and forecast155

7.2.Diagnostics157

7.2.1.Market size and forecast, by region158

7.2.2.Market analysis, by country159

7.3.Drug Discovery and Development160

7.3.1.Market size and forecast, by region161

7.3.2.Market analysis, by country162

7.4.Prognostics163

7.4.1.Market size and forecast, by region164

7.4.2.Market analysis, by country164

7.5.Risk Assessment166

7.5.1.Market size and forecast, by region166

7.5.2.Market analysis, by country167

7.6.Others168

7.6.1.Market size and forecast, by region169

7.6.2.Market analysis, by country170

CHAPTER 8:CANCER BIOMARKERS MARKET, BY REGION172

8.1.Overview172

8.1.1.Market size and forecast173

8.2.North America174

8.2.1.Key market trends and opportunities174

8.2.2.Market analysis by country175

8.2.2.1.U.S.176

8.2.2.1.1.U.S. market size and forecast, by profiling technologies176

8.2.2.1.2.U.S. market size and forecast, by biomolecules177

8.2.2.1.3.U.S. market size and forecast, by cancer type178

8.2.2.1.4.U.S. market size and forecast, by application179

8.2.2.2.Canada180

8.2.2.2.1.Canada market size and forecast, by profiling technologies180

8.2.2.2.2.Canada market size and forecast, by biomolecules182

8.2.2.2.3.Canada market size and forecast, by cancer type183

8.2.2.2.4.Canada market size and forecast, by application184

8.2.2.3.Mexico185

8.2.2.3.1.Mexico market size and forecast, by profiling technologies185

8.2.2.3.2.Mexico market size and forecast, by biomolecules187

8.2.2.3.3.Mexico market size and forecast, by cancer type188

8.2.2.3.4.Mexico market size and forecast, by application189

8.2.3.North America market size and forecast, by profiling technologies190

8.2.4.North America market size and forecast, by biomolecules191

8.2.5.North America market size and forecast, by cancer type192

8.2.6.North America market size and forecast, by application193

8.3.Europe194

8.3.1.Key market trends and opportunities194

8.3.2.Market analysis by country195

8.3.2.1.Germany197

8.3.2.1.1.Germany market size and forecast, by profiling technologies197

8.3.2.1.2.Germany market size and forecast, by biomolecules199

8.3.2.1.3.Germany market size and forecast, by cancer type200

8.3.2.1.4.Germany market size and forecast, by application201

8.3.2.2.France202

8.3.2.2.1.France market size and forecast, by profiling technologies202

8.3.2.2.2.France market size and forecast, by biomolecules204

8.3.2.2.3.France market size and forecast, by cancer type205

8.3.2.2.4.France market size and forecast, by application206

8.3.2.3.UK207

8.3.2.3.1.UK market size and forecast, by profiling technologies207

8.3.2.3.2.UK market size and forecast, by biomolecules208

8.3.2.3.3.UK market size and forecast, by cancer type209

8.3.2.3.4.UK market size and forecast, by application210

8.3.2.4.Italy211

8.3.2.4.1.Italy market size and forecast, by profiling technologies211

8.3.2.4.2.Italy market size and forecast, by biomolecules212

8.3.2.4.3.Italy market size and forecast, by cancer type213

8.3.2.4.4.Italy market size and forecast, by application214

8.3.2.5.Russia215

8.3.2.5.1.Russia market size and forecast, by profiling technologies215

8.3.2.5.2.Russia market size and forecast, by biomolecules217

8.3.2.5.3.Russia market size and forecast, by cancer type218

8.3.2.5.4.Russia market size and forecast, by application219

8.3.2.6.Rest of Europe220

8.3.2.6.1.Rest of Europe market size and forecast, by profiling technologies220

8.3.2.6.2.Rest of Europe market size and forecast, by biomolecules222

8.3.2.6.3.Rest of Europe market size and forecast, by cancer type223

8.3.2.6.4.Rest of Europe market size and forecast, by application224

8.3.3.Europe market size and forecast, by profiling technologies225

8.3.4.Europe market size and forecast, by biomolecules226

8.3.5.Europe market size and forecast, by cancer type227

8.3.6.Europe market size and forecast, by application228

8.4.Asia-Pacific229

8.4.1.Key market trends and opportunities229

8.4.2.Market analysis by country230

8.4.2.1.Japan231

8.4.2.1.1.Japan market size and forecast, by profiling technologies231

8.4.2.1.2.Japan market size and forecast, by biomolecules233

8.4.2.1.3.Japan market size and forecast, by cancer type234

8.4.2.1.4.Japan market size and forecast, by application235

8.4.2.2.China236

8.4.2.2.1.China market size and forecast, by profiling technologies236

8.4.2.2.2.China market size and forecast, by biomolecules237

8.4.2.2.3.China market size and forecast, by cancer type238

8.4.2.2.4.China market size and forecast, by application239

8.4.2.3.Australia240

8.4.2.3.1.Australia market size and forecast, by profiling technologies240

8.4.2.3.2.Australia market size and forecast, by biomolecules242

8.4.2.3.3.Australia market size and forecast, by cancer type243

8.4.2.3.4.Australia market size and forecast, by application244

8.4.2.4.India245

8.4.2.4.1.India market size and forecast, by profiling technologies245

8.4.2.4.2.India market size and forecast, by biomolecules246

8.4.2.4.3.India market size and forecast, by cancer type247

8.4.2.4.4.India market size and forecast, by application248

8.4.2.5.Rest of Asia-Pacific249

8.4.2.5.1.Rest of Asia-Pacific market size and forecast, by profiling technologies249

8.4.2.5.2.Rest of Asia-Pacific market size and forecast, by biomolecules250

8.4.2.5.3.Rest of Asia-Pacific market size and forecast, by cancer type251

8.4.2.5.4.Rest of Asia-Pacific market size and forecast, by application252

8.4.3.Asia-Pacific market size and forecast, by profiling technologies253

8.4.4.Asia-Pacific market size and forecast, by biomolecules254

8.4.5.Asia-Pacific market size and forecast, by cancer type255

8.4.6.Asia-Pacific market size and forecast, by application256

8.5.LAMEA257

8.5.1.Key market trends and opportunities257

8.5.2.Market analysis by country258

8.5.2.1.Brazil260

8.5.2.1.1.Brazil market size and forecast, by profiling technologies260

8.5.2.1.2.Brazil market size and forecast, by biomolecules261

8.5.2.1.3.Brazil market size and forecast, by cancer type262

8.5.2.1.4.Brazil market size and forecast, by application263

8.5.2.2.Saudi Arabia264

8.5.2.2.1.Saudi Arabia market size and forecast, by profiling technologies264

8.5.2.2.2.Saudi Arabia market size and forecast, by biomolecules266

8.5.2.2.3.Saudi Arabia market size and forecast, by cancer type267

8.5.2.2.4.Saudi Arabia market size and forecast, by application268

8.5.2.3.United Arab Emirates269

8.5.2.3.1.United Arab Emirates market size and forecast, by profiling technologies269

8.5.2.3.2.United Arab Emirates market size and forecast, by biomolecules270

8.5.2.3.3.United Arab Emirates market size and forecast, by cancer type271

8.5.2.3.4.United Arab Emirates market size and forecast, by application272

8.5.2.4.Rest of LAMEA273

8.5.2.4.1.Rest of LAMEA market size and forecast, by profiling technologies273

8.5.2.4.2.Rest of LAMEA market size and forecast, by biomolecules275

8.5.2.4.3.Rest of LAMEA market size and forecast, by cancer type276

8.5.2.4.4.Rest of LAMEA market size and forecast, by application277

8.5.3.LAMEA market size and forecast, by profiling technologies278

8.5.4.LAMEA market size and forecast, by biomolecules279

8.5.5.LAMEA market size and forecast, by cancer type280

8.5.6.LAMEA market size and forecast, by application281

CHAPTER 9:COMPANY PROFILES282

9.1.Abbott Laboratories282

9.1.1.Company overview282

9.1.2.Company snapshot282

9.1.3.Operating business segments283

9.1.4.Product portfolio283

9.1.5.Business performance285

9.2.BIO-RAD LABORATORIES, INC.287

9.2.1.Company overview287

9.2.2.Company snapshot288

9.2.3.Operating business segments289

9.2.4.Product Portfolio289

9.2.5.Business performance290

9.3.Bristol-Myers Squibb Company292

9.3.1.Company overview292

9.3.2.Company snapshot293

9.3.3.Operating business segments293

9.3.4.Product portfolio294

9.3.5.Business performance294

9.3.6.Key strategic moves and developments296

9.5.EXACT SCIENCES CORPORATION297

9.5.1.Company overview297

9.5.2.Company snapshot297

9.5.3.Operating business segments298

9.5.4.Product portfolio298

9.5.5.Business performance299

9.5.6.Key strategic moves and developments299

9.6.F. HOFFMANN-LA ROCHE LTD.301

9.6.1.Company overview301

9.6.2.Company snapshot301

9.6.3.Operating business segments302

9.6.4.Product portfolio303

9.6.5.Business performance304

305

9.6.6.Key strategic moves and developments306

9.7.Merck KGaA307

9.7.1.Company overview307

9.7.2.Company snapshot307

9.7.3.Operating business segments308

9.7.4.Product portfolio308

9.7.5.Business performance309

9.7.6.Key strategic moves and developments311

9.8.PERKINELMER, INC.312

9.8.1.Company overview312

9.8.2.Company snapshot312

9.8.3.Operating business segments313

9.8.4.Product portfolio314

9.8.5.Business performance315

9.8.6.Key strategic moves and developments317

9.9.QIAGEN N.V.318

9.9.1.Company overview318

9.9.2.Company snapshot318

9.9.3.Operating business segments319

9.9.4.Product portfolio320

9.9.5.Business performance320

9.9.6.Key strategic moves and developments322

9.10.Siemens AG323

9.10.1.Company overview323

9.10.2.Company snapshot324

9.10.3.Operating business segments324

9.10.4.Product portfolio325

9.10.5.Business performance326

9.11.THERMO FISHER SCIENTIFIC, INC.328

9.11.1.Company overview328

9.11.2.Company snapshot328

9.11.3.Operating business segments329

9.11.4.Product portfolio331

9.11.5.Business performance332

9.11.6.Key strategic moves and developments334

TABLE 01.CONVENTIONAL DIAGNOSTICS VS. DIAGNOSTIC BIOMARKER TECHNIQUES60

TABLE 02.GLOBAL CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGIES, 2019–2027 ($MILLION)86

TABLE 03.OMIC TECHNOLOGIES CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)89

TABLE 04.OMIC TECHNOLOGIES CANCER BIOMARKERS MARKET, BY TYPE, 2019–2027 ($MILLION)92

TABLE 05.GENOMICS CANCER BIOMARKERS MARKET, BY TYPE, 2019–2027 ($MILLION)93

TABLE 06.PROTEOMICS CANCER BIOMARKERS MARKET, BY TYPE, 2019–2027 ($MILLION)97

TABLE 07.OTHER OMIC TECHNOLOGIES CANCER BIOMARKERS MARKET, BY TYPE, 2019–2027 ($MILLION)101

TABLE 08.IMAGING TECHNOLOGIES CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)105

TABLE 09.IMAGING TECHNOLOGIES CANCER BIOMARKERS MARKET, BY TYPE, 2019–2027 ($MILLION)107

TABLE 10.IMMUNOASSAYS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)116

TABLE 11.IMMUNOASSAYS CANCER BIOMARKERS MARKET, BY TYPE, 2019–2027 ($MILLION)118

TABLE 12.CYTOGENETICS-BASED TESTS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)124

TABLE 13.CYTOGENETICS-BASED TESTS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)127

TABLE 14.GLOBAL CANCER BIOMARKERS MARKET, BY BIOMOLECULE, BY BIOMOLECULE, 2019–2027 ($MILLION)131

TABLE 15.GENETIC BIOMARKERS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)134

TABLE 16.PROTEIN BIOMARKERS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)137

TABLE 17.GLYCO-BIOMARKERS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)140

TABLE 18.GLOBAL CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2019–2027 ($MILLION)144

TABLE 19.BREAST CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)146

TABLE 20.LUNG CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)149

TABLE 21.COLORECTAL CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)151

TABLE 22.PROSTATE CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)154

TABLE 23.STOMACH CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)157

TABLE 24.OTHERS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)160

TABLE 25.GLOBAL CANCER BIOMARKERS MARKET, BY APPLICATION, 2019–2027 ($MILLION)163

TABLE 26.DIAGNOSTICS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)165

TABLE 27.DRUG DISCOVERY AND DEVELOPMENT CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)169

TABLE 28.PROGNOSTICS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)171

TABLE 29.RISK ASSESSMENT CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)174

TABLE 30.OTHERS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)177

TABLE 31.CANCER BIOMARKERS MARKET, BY REGION, 2018-2026 ($MILLION)180

TABLE 32.NORTH AMERICA CANCER BIOMARKERS MARKET REVENUE, BY COUNTRY 2019–2026 ($MILLION)182

TABLE 33.THE U.S. CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)183

TABLE 34.THE U.S. CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)185

TABLE 35.THE U.S. CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)186

TABLE 36.THE U.S. CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)187

TABLE 37.CANADA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)188

TABLE 38.CANADA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)190

TABLE 39.CANADA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)191

TABLE 40.CANADA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)192

TABLE 41.MEXICO CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)193

TABLE 42.MEXICO CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)194

TABLE 43.MEXICO CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)195

TABLE 44.MEXICO CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)196

TABLE 45.NORTH AMERICA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)197

TABLE 46.NORTH AMERICA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)198

TABLE 47.NORTH AMERICA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)199

TABLE 48.NORTH AMERICA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)200

TABLE 49.EUROPE CANCER BIOMARKERS MARKET REVENUE, BY COUNTRY 2019–2026 ($MILLION)202

TABLE 50.GERMANY CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)204

TABLE 51.GERMANY CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)206

TABLE 52.GERMANY CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)207

TABLE 53.GERMANY CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)208

TABLE 54.GERMANY CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)209

TABLE 55.FRANCE CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)210

TABLE 56.FRANCE CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)211

TABLE 57.FRANCE CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)212

TABLE 58.UK CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)213

TABLE 59.UK CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)214

TABLE 60.UK CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)215

TABLE 61.UK CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)216

TABLE 62.ITALY CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)217

TABLE 63.ITALY CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)218

TABLE 64.ITALY CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)219

TABLE 65.ITALY CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)220

TABLE 66.RUSSIA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)221

TABLE 67.RUSSIA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)222

TABLE 68.RUSSIA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)223

TABLE 69.RUSSIA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)224

TABLE 70.REST OF EUROPE CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)225

TABLE 71.REST OF EUROPE CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)226

TABLE 72.REST OF EUROPE CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)227

TABLE 73.REST OF EUROPE CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)228

TABLE 74.EUROPE CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)229

TABLE 75.EUROPE CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)230

TABLE 76.EUROPE CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)231

TABLE 77.EUROPE CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)232

TABLE 78.ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY COUNTRY 2019–2026 ($MILLION)235

TABLE 79.JAPAN CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)236

TABLE 80.JAPAN CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)237

TABLE 81.JAPAN CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)238

TABLE 82.JAPAN CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)239

TABLE 83.CHINA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)240

TABLE 84.CHINA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)241

TABLE 85.CHINA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)242

TABLE 86.CHINA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)243

TABLE 87.AUSTRALIA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)244

TABLE 88.AUSTRALIA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)245

TABLE 89.AUSTRALIA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)246

TABLE 90.AUSTRALIA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)247

TABLE 91.INDIA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)248

TABLE 92.INDIA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)249

TABLE 93.INDIA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)250

TABLE 94.INDIA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)251

TABLE 95.REST OF ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)252

TABLE 96.REST OF ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)253

TABLE 97.REST OF ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)254

TABLE 98.REST OF ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)255

TABLE 99.ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)256

TABLE 100.ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)257

TABLE 101.ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)258

TABLE 102.ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)259

TABLE 103.LAMEA CANCER BIOMARKERS MARKET REVENUE, BY COUNTRY 2019–2026 ($MILLION)261

TABLE 104.BRAZIL CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)263

TABLE 105.BRAZIL CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)264

TABLE 106.BRAZIL CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)265

TABLE 107.BRAZIL CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)266

TABLE 108.SAUDI ARABIA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)267

TABLE 109.SAUDI ARABIA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)269

TABLE 110.SAUDI ARABIA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)270

TABLE 111.SAUDI ARABIA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)271

TABLE 112.UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)272

TABLE 113.UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)273

TABLE 114.UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)274

TABLE 115.UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)275

TABLE 116.REST OF LAMEA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)276

TABLE 117.REST OF LAMEA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)278

TABLE 118.REST OF LAMEA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)279

TABLE 119.REST OF LAMEA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)280

TABLE 120.LAMEA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)281

TABLE 121.LAMEA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)282

TABLE 122.LAMEA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)283

TABLE 123.LAMEA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)284

TABLE 124.ABBOTT: COMPANY SNAPSHOT285

TABLE 125.ABBOTT: OPERATING SEGMENTS286

TABLE 126.ABBOTT: PRODUCT PORTFOLIO287

TABLE 127.BIO-RAD: COMPANY SNAPSHOT291

TABLE 128.BIO-RAD: OPERATING SEGMENTS292

TABLE 129.BIO-RAD: PRODUCT PORTFOLIO292

TABLE 130.BMS: COMPANY SNAPSHOT296

TABLE 131.BMS: PRODUCT PORTFOLIO297

TABLE 132.EXACT SCIENCES: COMPANY SNAPSHOT300

TABLE 133.EXACT SCIENCES: PRODUCT PORTFOLIO301

TABLE 134.ROCHE: COMPANY SNAPSHOT304

TABLE 135.ROCHE: OPERATING SEGMENTS305

TABLE 136.ROCHE: PRODUCT PORTFOLIO306

TABLE 137.MERCK GROUP: COMPANY SNAPSHOT310

TABLE 138.MERCK GROUP: OPERATING SEGMENTS311

TABLE 139.MERCK GROUP: PRODUCT PORTFOLIO312

TABLE 140.PERKINELMER: COMPANY SNAPSHOT315

TABLE 141.PERKINELMER: OPERATING SEGMENTS316

TABLE 142.PERKINELMER: PRODUCT PORTFOLIO317

TABLE 143.QIAGEN: COMPANY SNAPSHOT321

TABLE 144.QIAGEN: OPERATING SEGMENTS322

TABLE 145.QIAGEN: PRODUCT PORTFOLIO323

TABLE 146.SIEMENS: COMPANY SNAPSHOT327

TABLE 147.SIEMENS: OPERATING SEGMENTS327

TABLE 148.SIEMENS: PRODUCT PORTFOLIO328

TABLE 149.THERMO FISHER: COMPANY SNAPSHOT331

TABLE 150.THERMO FISHER: OPERATING SEGMENTS332

TABLE 151.THERMO FISHER: PRODUCT PORTFOLIO334